坐骨神经痛市场规模、份额和成长分析（按疾病类型、药物类别、给药途径、分销管道和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，全球坐骨神经痛市场规模将达到 86.5 亿美元，到 2025 年将成长至 91.4 亿美元，到 2033 年将成长至 142.5 亿美元，在预测期（2026-2033 年）内，复合年增长率为 5.7%。

由于久坐的生活方式、人口老化以及脊椎疾病发病率的上升等因素导致坐骨神经痛盛行率不断增加，预计全球坐骨神经痛市场将显着增长。诊断技术和治疗方法的进步提高了坐骨神经痛诊断和治疗策略的准确性。人们对早期疗育和復原重要性的认识不断提高，也进一步推动了市场发展。然而，治疗成本上升、某些地区先进医疗设施匮乏以及手术可能带来的併发症等挑战可能会阻碍市场扩张。儘管如此，对微创手术的关注、新型治疗方法的涌现以及对个人化治疗方案日益增长的需求，预计将推动全球坐骨神经痛市场的成长。

全球坐骨神经痛市场驱动因素

全球坐骨神经痛市场受到普遍缺乏对该疾病认知和漏诊率高的影响。久坐的生活方式、不良姿势、肥胖以及人口老化等因素导致坐骨神经痛的盛行率不断上升。这导致人们对有效的诊断工具、各种治疗方法和疼痛管理方案的需求日益增长。这一趋势正在推动市场扩张，并凸显了改善坐骨神经痛患者教育和治疗方案的必要性，最终目标是改善患者的健康和生活品质。

全球坐骨神经痛市场的限制因素

全球坐骨神经痛市场面临的一大挑战是大众对该疾病普遍缺乏了解，以及治疗常常被忽视。许多坐骨神经痛患者未能识别自身症状或寻求必要的医疗协助，导致诊断和治疗延迟。此外，医疗服务资源匮乏，尤其是在农村地区，进一步加剧了这个问题，延缓了坐骨神经痛的有效治疗。透过教育活动提高公众意识，并改善医疗基础设施，是缓解这项挑战、最终改善坐骨神经痛患者诊断和治疗效果的重要措施。

全球坐骨神经痛市场趋势

全球坐骨神经痛治疗市场的一个显着趋势是，微创治疗方法越来越受到青睐，这反映了医疗保健领域向微创技术的转变。内视镜切除术和经皮减压术等技术因其优于传统手术的许多优势而备受关注，这些优势包括切口更小、组织损伤更少、恢復更快以及风险更低。这一趋势主要源于患者对有效缓解疼痛且併发症更少的需求，以及医疗服务提供者对改善患者疗效和降低成本的重视。因此，随着患者和临床医生越来越接受这些创新治疗方案，市场正经历强劲成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 一手和二手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 技术评估
• 专利分析

全球坐骨神经痛市场规模（按疾病类型和复合年增长率划分）（2026-2033 年）

• 急性坐骨神经痛
• 慢性坐骨神经痛
• 其他的

全球坐骨神经痛市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 非类固醇消炎剂
• 口服类固醇
• 抗惊厥药
• 三环抗忧郁药物
• 阿片类镇痛药
• 其他的

全球坐骨神经痛市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 注射

全球坐骨神经痛市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房

全球坐骨神经痛市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • GCC
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

  主要企业简介

  • 美敦力公司（爱尔兰）
  • 强生公司（美国）
  • Zimmer Biomet Holdings, Inc.（美国）
  • 梯瓦製药工业股份有限公司（以色列）
  • 赛诺菲公司（法国）
  • 诺华国际股份公司（瑞士）
  • 百时美施贵宝公司（美国）
  • 默克公司（美国）
  • Zynex公司（美国）
  • 索伦托治疗公司（美国）
  • Hikma Pharmaceuticals PLC（英国）
  • Viatris公司（美国）
  • 波士顿科学公司（美国）
  • 雅培实验室（美国）
  • 史赛克公司（美国）
  • 葛兰素史克有限公司（英国）
  • 阿斯特捷利康有限公司（英国）
  • 礼来公司（美国）
  • 百时美施贵宝公司（美国）

结论与建议

Global Sciatica Market size was valued at USD 8.65 Billion in 2024 and is poised to grow from USD 9.14 Billion in 2025 to USD 14.25 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

Significant growth is anticipated in the global sciatica market, driven by the escalating prevalence of the condition, influenced by sedentary lifestyles, an aging population, and rising spinal disorders. Advancements in diagnostic technologies and treatment options enhance the accuracy of diagnoses and management strategies for sciatica. Increased awareness regarding the importance of early intervention and rehabilitation is further fueling market development. However, challenges such as high treatment costs, limited access to advanced healthcare facilities in certain areas, and potential surgical complications may hinder expansion. Nonetheless, the focus on minimally invasive procedures, the emergence of novel therapeutics, and the rising demand for personalized treatment approaches will likely propel the growth of the global sciatica market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Market Segments Analysis

Global Sciatica Market is segmented by Disease Type, Drug Class, Route of Administration, Distribution Channel and region. Based on Disease Type, the market is segmented into Acute Sciatica, Chronic Sciatica and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Market

The global sciatica market is significantly influenced by the widespread lack of awareness and frequent underdiagnosis of the condition. Contributing factors include sedentary lifestyles, poor posture, obesity, and an aging population, all of which lead to an increasing prevalence of sciatica. As a result, there is a growing demand for effective diagnostic tools as well as various therapies and pain management solutions. This trend fosters market expansion and highlights the necessity for improved education and treatment options for individuals affected by sciatica, ultimately enhancing overall health outcomes and quality of life for sufferers.

Restraints in the Global Sciatica Market

A significant challenge facing the global sciatica market is the general lack of awareness and frequent underdiagnosis of the condition. Numerous individuals experiencing sciatica may fail to identify their symptoms or may not pursue the necessary medical assistance, resulting in postponed diagnosis and treatment. Additionally, restricted access to healthcare services, particularly in rural regions, exacerbates the issue by delaying effective management of sciatica. Enhancing awareness through educational initiatives and improving healthcare infrastructure are essential steps that could alleviate this challenge, ultimately leading to better diagnosis and treatment outcomes for those affected by sciatica.

Market Trends of the Global Sciatica Market

A prominent trend in the global sciatica market is the rising preference for minimally invasive treatment options, reflecting a shift towards less invasive methodologies in healthcare. Techniques such as endoscopic discectomy and percutaneous decompression are gaining traction due to their numerous benefits, including reduced incision size, decreased tissue damage, quicker recovery times, and minimized risks compared to traditional surgical procedures. This trend is largely influenced by patient demand for effective pain relief with fewer complications, as well as healthcare providers' focus on enhancing patient outcomes and driving down costs. Consequently, the market is experiencing robust growth as both patients and clinicians increasingly embrace these innovative treatment solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Technology Assessment
• Patent Analysis

Global Sciatica Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Acute Sciatica
• Chronic Sciatica
• Others

Global Sciatica Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs
• Oral Steroids
• Anticonvulsant Agents
• Tricyclic Antidepressants
• Opioid Analgesics
• Others

Global Sciatica Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Sciatica Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Sciatica Market Size & CAGR (2026-2033)

• North America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynex Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations